Overall, 240 patients were randomly assigned to bDCF (n = 121) or CF (n = 119). The median follow-up period was 15.3 months (IQR, 8.9-26.2). The median OS was 16.2 (95% CI, 13.8 to 20.4) and 14.8 (95% ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Dec. 4, 2003 (San Antonio) — Docetaxel (Taxotere) produced better overall survival and longer time to progression than paclitaxel (Taxol) in a randomized head-to-head trial of the two taxanes widely ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

Prognostic assessment of pre- and post-neoadjuvant SUVs via 18F-FDG PET/CT in esophageal cancer patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...